Updated:
National Institute of Mental Health
The National Institute of Mental Health is a research organization founded in 1946 in North Bethesda, Maryland. It provides funding for mental health research,...
National Institute of Mental Health
The National Institute of Mental Health is a research organization founded in 1946 in North Bethesda, Maryland. It provides funding for mental health research, supports clinical trials, and offers educational resources. The organization serves the mental health research community, healthcare professionals, and individuals seeking mental health information.
General information
Firm type
other
Year founded
1949
Location
Region
North America
Country
United States
City
Bethesda
Corporate office
Bethesda, MD, United States
Principals
Joshua A. Gordon
Director
Sector focus
Frequently asked questions
Who runs investment decisions at NIMH?
The NIMH Director, currently Joshua A. Gordon, sets the overall scientific strategy, but grant funding decisions are made through competitive peer review overseen by the Institute's National Advisory Mental Health Council, which includes academic researchers, clinicians, and public members (per the NIMH website, public record).
How does NIMH source its research portfolio?
NIMH issues funding opportunity announcements (FOAs) for investigator-initiated grants, cooperative agreements, and contracts. It also solicits targeted research through Requests for Applications (RFAs) aligned with its strategic priorities. Proposals are evaluated by independent peer-review panels, not NIMH staff alone (per the NIMH grants policy, public record).
Is NIMH structured as a single fund or does it operate more like a venture firm?
NIMH is a federal agency — it does not have a central investment pool or capital allocation process. Its 'portfolio' is a set of ~1,800 active research grants and contracts, awarded via competitive review, not direct investment decisions. There is no internal fund-of-funds or direct equity holdings.
Does NIMH participate in fund commitments or only direct grants?
NIMH exclusively awards grants and cooperative agreements; it does not invest in private funds, take equity positions, or participate in limited-partner commitments. All funding goes to research institutions, universities, and nonprofit organizations (per the NIH Grants Policy Statement).
What investment stages does NIMH typically target?
NIMH funds research across the full translational spectrum: basic neuroscience (R01 grants), preclinical development (R41/R42 SBIR grants), clinical trials (U01/U10 cooperative agreements), and implementation science (R18 grants). It does not fund late-stage commercial product development or clinical-stage companies.
Which sectors does NIMH explicitly avoid?
NIMH does not fund human-subject research that does not align with its strategic priorities (e.g., cosmetic neurology, non-mental-health psychiatric drug development). It also does not fund patient care, construction, or non-research training programs (per the NIMH Strategic Plan, public record).
Where does the funding for NIMH come from?
NIMH is funded through annual congressional appropriations as part of the US federal budget. For fiscal year 2023, the appropriation was approximately $1.8B. It does not accept private donations, endowments, or commercial investments (per the NIH budget office, public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: